SS-31
SS-31 / Elamipretide (Bendavia)
Mitochondria-protective peptide
LongevityAnti-Aging ★ 70
Half-life
~2-3 hours (SubQ)
Cycle
8-16 week cycles, with a 4-week break.
Storage
Lyophilized: refrigerated. Reconstituted: 2-8°C, 30 days.
Research
Phase 3 (Stealth BioTherapeutics), orphan drug status for Barth syndrome
About
A small peptide that binds the inner mitochondrial membrane and reduces cardiolipin oxidation. Phase 3 trials in primary mitochondrial myopathy and heart failure.
Mechanism
Binds cardiolipin in the inner mitochondrial membrane, protects the electron transport chain, reduces ROS.
Dosage
20 mg
1x per day
0102030405060708090100
Draw to 200 units on a U-100 insulin syringe
10 mg · 1 mL BAC
Route
Subcutaneous (SubQ)
Duration
4-8 weeks
When to take: Best in the morning — energy-related effects.
Reconstitution
Vial size (mg): 10 mg · BAC water (mL): 1 mL · Concentration: 10 mg/mL
Larger vials require larger bac volumes due to mg quantity.
Dosing reference
Units to draw at the typical dose range, per vial size.
| Vial | Water | Typical draw |
|---|---|---|
| 10 mg | 1 mL | 50 units |
| 15 mg | 1 mL | 33.5 units |
Benefits
- Protects mitochondria
- Improved energy and endurance
- Cardioprotective effects
- Possibly anti-aging via mitochondrial biogenesis
- Reduced muscle fatigue
Side effects
- Injection-site irritation
- Rare: headache
- Well tolerated in clinical trials
Gender notes
Same dose as general protocol.
Cautions
- Limited pregnancy data
- Drug interactions not yet fully studied
Research
- Karaa et al: SS-31 in mitochondrial myopathy
Neurology · 2020
MMPOWER-3 trial in primary mitochondrial myopathy.